X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-26 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale | $44.05 | -4,707 | 7,863 | -37% | -$207,327 | ||||||
| A | 2021-12-29 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | P - Purchase | $14.24 | +1,752 | 5,981 | +41% | +$24,948 | |||||
| A | 2021-12-28 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | P - Purchase | $12.84 | +2,338 | 4,229 | +124% | +$30,028 | |||||
2025-06-27 | TERN | Terns Pharmaceuticals, Inc. | Gengos Andrew | CFO | P - Purchase | $3.93 | +10,000 | 25,000 | +67% | +$39,283 | ||||||
2025-06-26 | ZVRA | Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal, Compliance | S - Sale | $9.21 | -24,000 | 42,666 | -36% | -$221,004 | ||||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Bios Equity Cof, LP | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Kreis Leslie W. | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
| D | 2025-06-27 | ACTU | Actuate Therapeutics, Inc. | Fletcher Aaron G.L. | Dir, 10% | P - Purchase | $7.00 | +71,428 | 10,196,456 | +1% | +$499,996 | |||||
2025-06-27 | IMRX | Immuneering Corp | Schall Thomas J. | Dir | P - Purchase | $3.66 | +9,500 | 52,885 | +22% | +$34,788 | ||||||
2025-06-26 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.44 | +4,500 | 997,410 | 0% | +$6,483 | ||||||
| D | 2025-06-26 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $78.71 | -4,000 | 48,034 | -8% | -$314,826 | |||||
| DM | 2025-06-25 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $79.88 | -10,800 | 63,101 | -15% | -$862,705 | |||||
| D | 2025-06-26 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $285.70 | -11,000 | 36,781 | -23% | -$3,142,718 | |||||
2025-06-27 | NATR | Natures Sunshine Products Inc | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $11.46 | -2,854,607 | 64,167 | -98% | -$32,713,796 | ||||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $36.13 | -5,877 | 39,098 | -13% | -$212,348 | |||||
2025-06-25 | AIMD | Ainos, Inc. | Lee Ting-Chuan | Dir | S - Sale | $0.51 | -2,894 | 1,428,538 | 0% | -$1,476 | ||||||
| M | 2025-06-25 | AIMD | Ainos, Inc. | Tsai Chun-Jung | Dir | S - Sale | $0.50 | -17,000 | 1,384,997 | -1% | -$8,540 | |||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $36.13 | -23,669 | 514,982 | -4% | -$855,208 | |||||
| D | 2025-06-26 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $36.13 | -2,675 | 21,004 | -11% | -$96,653 | |||||
| D | 2025-06-24 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $7.06 | -16,344 | 937,419 | -2% | -$115,366 | |||||
2025-06-24 | KALA | Kala Bio, Inc. | Kharabi Darius | CHIEF BUSINESS OFFICER | S - Sale | $4.01 | -4,511 | 62,566 | -7% | -$18,089 | ||||||
| D | 2025-06-24 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale+OE | $7.02 | -13,321 | 73,056 | -15% | -$93,447 | |||||
2025-06-24 | KALA | Kala Bio, Inc. | Reumuth Mary | CFO | S - Sale | $4.01 | -3,631 | 62,100 | -6% | -$14,560 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Bazemore Todd | SEE REMARKS | S - Sale | $4.01 | -4,058 | 83,700 | -5% | -$16,273 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Brazzell Romulus K | SEE REMARKS | S - Sale | $4.01 | -5,251 | 82,698 | -6% | -$21,057 | ||||||
2025-06-24 | KALA | Kala Bio, Inc. | Iwicki Mark T | Dir | S - Sale | $4.01 | -13,227 | 258,433 | -5% | -$53,040 | ||||||
| M | 2025-06-24 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $18.38 | +3,780 | 6,827,133 | 0% | +$69,466 | |||||
| D | 2025-06-26 | CALC | Calcimedica, Inc. | Bardin Stephen | CFO | P - Purchase | $1.50 | +2,000 | 43,000 | +5% | +$3,005 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Burns James William | GC | S - Sale+OE | $33.54 | -2,799 | 28,650 | -9% | -$93,878 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $33.54 | -2,909 | 56,988 | -5% | -$97,568 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $33.54 | -1,780 | 30,049 | -6% | -$59,701 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $33.54 | -2,770 | 26,122 | -10% | -$92,906 | |||||
| D | 2025-06-24 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $33.54 | -18,700 | 111,922 | -14% | -$627,198 | |||||
2025-06-24 | BBIO | Bridgebio Pharma, Inc. | McCormick Frank | Dir | S - Sale | $44.23 | -100,000 | 963,254 | -9% | -$4,422,800 | ||||||
2025-06-25 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $4.38 | +2,500 | 174,228 | +1% | +$10,939 | ||||||
| M | 2025-06-23 | VERA | Vera Therapeutics, Inc. | Enright Patrick G | Dir | P - Purchase | $21.11 | +250,000 | 3,596,593 | +7% | +$5,277,311 | |||||
| D | 2025-06-25 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale+OE | $13.86 | -10,000 | 122,279 | -8% | -$138,642 | |||||
| D | 2025-06-24 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.02 | -12,000 | 110,886 | -10% | -$168,218 | |||||
| D | 2025-06-24 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale+OE | $14.00 | -15,000 | 216,485 | -6% | -$210,000 | |||||
2025-06-23 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.38 | -88 | 3,594 | -2% | -$210 | ||||||
2025-06-23 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.38 | -303 | 12,906 | -2% | -$722 | ||||||
2025-06-25 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | P - Purchase | $3.87 | +23,314 | 47,083 | +98% | +$90,230 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $260.00 | -1,028 | 1,755,494 | 0% | -$267,280 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $260.00 | -1,363 | 1,244,693 | 0% | -$354,380 | ||||||
2025-06-24 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale | $265.50 | -2,007 | 10,132,983 | 0% | -$532,867 | ||||||
2025-06-23 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $261.61 | -3,174 | 54,229,075 | 0% | -$830,360 | ||||||
2025-06-23 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $0.00 | -29,476 | 5,470,524 | -1% | -$0 | ||||||
2025-06-24 | UTHR | United Therapeutics Corp | Mesa Nilda | Dir | S - Sale | $289.99 | -645 | 4,883 | -12% | -$187,045 | ||||||
| D | 2025-06-24 | UTHR | United Therapeutics Corp | Giltner Richard | Dir | S - Sale+OE | $289.60 | -3,036 | 19,384 | -14% | -$879,214 | |||||
| M | 2025-06-23 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.16 | +6,146 | 277,574 | +2% | +$7,120 | |||||
| D | 2025-06-23 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $101.78 | -57,765 | 93,536 | -38% | -$5,879,089 | |||||
2025-06-23 | AIMD | Ainos, Inc. | Ase Test, Inc. | 10% | P - Purchase | $0.00 | +29,476 | 58,887 | +100% | +$0 | ||||||
| D | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.45 | -100,000 | 1,462,223 | -6% | -$1,145,000 | |||||
2025-06-23 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $114.08 | -500 | 31,903 | -2% | -$57,042 | ||||||
| M | 2025-06-23 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale | $10.49 | -33,500 | 68,317 | -33% | -$351,384 | |||||
2025-06-20 | QURE | Uniqure N.V. | Springhorn Jeremy P. | Dir | S - Sale | $14.45 | -2,112 | 37,694 | -5% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Post Leonard E | Dir | S - Sale | $14.45 | -2,112 | 29,937 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale | $14.45 | -2,112 | 20,439 | -9% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Jacques Rachelle Suzanne | Dir | S - Sale | $14.45 | -2,112 | 28,346 | -7% | -$30,518 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale | $14.45 | -3,336 | 56,879 | -6% | -$48,205 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale | $14.45 | -2,112 | 37,697 | -5% | -$30,518 | ||||||
2025-06-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $21.40 | -12,500 | 965,188 | -1% | -$267,458 | ||||||
2025-06-20 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $14.45 | -2,112 | 34,190 | -6% | -$30,518 | ||||||
2025-06-20 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% | P - Purchase | $7.99 | +5,603 | 3,091,127 | 0% | +$44,768 | ||||||
2025-06-20 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.13 | -17,808 | 443,839 | -4% | -$91,355 | ||||||
| M | 2025-06-20 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $5.13 | -4,135 | 109,920 | -4% | -$21,202 | |||||
2025-06-20 | AKTX | Akari Therapeutics Plc | Gaslightwala Abizer | Pres, CEO | P - Purchase | $1.20 | +10,000 | 271,428 | +4% | +$12,000 | ||||||
2025-06-24 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $7.61 | -5,700 | 164,401 | -3% | -$43,377 | ||||||
| D | 2025-06-20 | MRUS | Merus N.V. | Silverman Peter B. | COO, GC | S - Sale+OE | $52.76 | -34,000 | 0 | -100% | -$1,793,840 | |||||
2025-06-24 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $4.05 | +5,000 | 360,900 | +1% | +$20,250 | ||||||
| M | 2025-06-20 | IMRX | Immuneering Corp | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | P - Purchase | $2.58 | +13,422 | 359,318 | +4% | +$34,616 | |||||
2025-06-20 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Chief Business Officer | P - Purchase | $2.53 | +1,900 | 5,800 | +49% | +$4,804 | ||||||
2025-06-20 | THAR | Tharimmune, Inc. | Gravitas Capital LP | Exec COB, 10% | P - Purchase | $1.48 | +337,838 | 732,424 | +86% | +$500,000 | ||||||
| M | 2025-06-20 | ORIC | Oric Pharmaceuticals, Inc. | You Angie | Dir | P - Purchase | $9.39 | +28,000 | 28,000 | New | +$262,899 | |||||
| M | 2025-06-18 | AIMD | Ainos, Inc. | Tsai Chun-Jung | Dir | S - Sale | $0.53 | -25,903 | 1,401,997 | -2% | -$13,624 | |||||
| DM | 2025-06-20 | AXSM | Axsome Therapeutics, Inc. | Murdock Hunter R. | GC | S - Sale+OE | $101.42 | -13,514 | 0 | -100% | -$1,370,647 | |||||
2025-06-20 | THAR | Tharimmune, Inc. | Parikh Sanam | Dir | P - Purchase | $1.45 | +1,000 | 1,770 | +130% | +$1,450 | ||||||
2025-06-20 | THAR | Tharimmune, Inc. | Appajosyula Sireesh | CEO | P - Purchase | $1.48 | +61,496 | 64,868 | >999% | +$90,973 | ||||||
| D | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | Foster Jonathan P. | CFO | P - Purchase | $0.37 | +270,270 | 287,587 | >999% | +$100,000 | |||||
| D | 2025-06-23 | MBRX | Moleculin Biotech, Inc. | Klemp Walter V | CEO, Pres | P - Purchase | $0.37 | +675,675 | 743,607 | +995% | +$250,000 | |||||
2025-06-20 | ZLAB | Zai Lab Ltd | Lis William | Dir | S - Sale | $35.67 | -13,814 | 35,106 | -28% | -$492,745 | ||||||
2025-06-20 | SVRA | Savara Inc | Hawkins Richard J | Dir | P - Purchase | $2.04 | +48,225 | 115,466 | +72% | +$98,572 | ||||||
2025-06-20 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Dir | S - Sale | $37.39 | -2,405 | 15,344 | -14% | -$89,923 | ||||||
| M | 2025-06-18 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $11.46 | -1,142,273 | 50,641,965 | -2% | -$13,084,796 | |||||
2025-06-13 | RZLT | Rezolute, Inc. | Kim Young-Jin | Dir | P - Purchase | $3.25 | +1,230,769 | 8,573,336 | +17% | +$3,999,999 | ||||||
2025-06-13 | RZLT | Rezolute, Inc. | Kreher Nerissa | Dir | P - Purchase | $3.25 | +3,076 | 37,576 | +9% | +$9,997 | ||||||
2025-06-18 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $2.53 | +25,000 | 1,121,064 | +2% | +$63,188 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $54.84 | -6,620 | 549,867 | -1% | -$363,041 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Gangloff Scott A. | CTO | S - Sale | $54.84 | -848 | 23,452 | -3% | -$46,504 | ||||||
2025-06-20 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale | $54.59 | -875 | 31,698 | -3% | -$47,766 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $54.84 | -1,129 | 166,234 | -1% | -$61,914 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $54.84 | -1,634 | 57,521 | -3% | -$89,609 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $54.84 | -1,633 | 90,598 | -2% | -$89,554 | ||||||
2025-06-18 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $54.84 | -1,453 | 256,594 | -1% | -$79,683 | ||||||
| D | 2025-06-20 | CNTA | Centessa Pharmaceuticals Plc | Saha Saurabh | CEO | S - Sale+OE | $12.63 | -55,000 | 259,017 | -18% | -$694,826 | |||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $1.20 | -486 | 26,530 | -2% | -$583 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $1.20 | -1,522 | 178,802 | -1% | -$1,825 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Harler Mary Beth | CEO | S - Sale | $1.20 | -1,522 | 338,181 | 0% | -$1,825 | ||||||
2025-06-16 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $1.20 | -951 | 72,578 | -1% | -$1,140 | ||||||
| DM | 2025-06-17 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $6.74 | -339,720 | 912,419 | -27% | -$2,289,781 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |